Myelodysplastic Syndrome


Drugs can increase risk of MDS and AML

A class of immunosuppressive agents appear to increase the risk of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in patients...

Conference Coverage

Lower-dose quizartinib diminishes QT events

Major finding: An increase in QTcF from baseline of more than 60 msec was seen in 19% of patients on quizartinib 60 mg and in 3% of those on 30 mg...


Drug gets orphan designation for MDS

The drug, CPI-613, targets metabolic changes that are thought to occur in many cancer cells. It has demonstrated activity and tolerability in a...